Sugammadex is not metabolised nor excreted by the liver; therefore dedicated studies in patients with hepatic impairment have not been conducted.
Sugammadeksi ei metaboliseerita ega elimineerita maksa kaudu, seetõttu ei ole vastavaid uuringuid maksakahjustusega patsientide kohta läbi viidud.